Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKCRMD)

Drug Name
AVB-S6-500 Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMKCRMD

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Tyrosine-protein kinase UFO (AXL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gilteritinib DMTI0ZO Acute myeloid leukaemia 2A60 Approved [1]
MGCD265 DMRPCF2 Non-small-cell lung cancer 2C25.Y Phase 2 [2]
BI-505 DMSZQHX Multiple myeloma 2A83 Phase 2 [3]
Bemcentinib DM0YCPL Myelodysplastic syndrome 2A37 Phase 2 [4]
BGB-324 DMDI43Y Breast cancer 2C60-2C65 Phase 2 [5]
Mecbotamab vedotin DMU5KH4 Ovarian cancer 2C73 Phase 2 [6]
ONO-7475 DMV6GX7 Acute leukaemia 2A60 Phase 1/2 [1]
ONO-7475 DMV6GX7 Acute leukaemia 2A60 Phase 1/2 [7]
TP-0903 DMHTG8P Chronic lymphocytic leukaemia 2A82.0 Phase 1/2 [1]
Enapotamab vedotin DM1PQJO Solid tumour/cancer 2A00-2F9Z Phase 1/2 [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tyrosine-protein kinase UFO (AXL) TTZPY6J UFO_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Company report (Mirati Therapeutics: formerly MethylGene)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. J Thorac Oncol. 2020 Jun;15(6):973-999.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1835).
6 Clinical pipeline report, company report or official report of BioAtla
7 Clinical pipeline report, company report or official report of Ono Pharmaceutical.
8 Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight. 2019 Nov 1;4(21):e128199.